1. Approval of the Annual Report for the Financial Year 2024-25. 2. Approval of notice of 32nd AGM and fixation of day, date, time and venue of the meeting. 3. Appointment of Secretarial ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Directors of Kimia Biosciences met on August 29, 2025, and approved the Annual Report for FY 2024-25 along with the notice for the 32nd Annual General Meeting, fixed for Tuesday, September 30, 2025, to be held via video conferencing. The Board appointed Mr. Harish Kumar as Secretarial Auditor and re-appointed M/s Neeraj Arora & Associates as Statutory Auditor, both for a 5-year term (FY 2025-26 to FY 2029-30). Mr. Sameer Goel, Managing Director & CEO, was re-appointed as a director liable to retire by rotation. Cost Auditor remuneration was approved, and NSDL was appointed to provide e-voting and VC facilities for the AGM. Record date and cut-off date for e-voting were also fixed.
This is a routine administrative filing with no material change for shareholders – standard AGM approvals, auditor re-appointments, and re-appointment of the existing Managing Director. No impact expected on stock price or shareholder value.